Premium
O4‐03‐01: MICROGLIAL EXPRESSION OF ALZHEIMER'S DISEASE ASSOCIATED RISK GENES
Author(s) -
Kofler Julia,
Wang Xingbin,
Kamboh Ilyas,
Sweet Robert,
Lopez Oscar,
Murdoch Geoffrey
Publication year - 2014
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2014.04.396
Subject(s) - genome wide association study , biology , trem2 , microglia , gene , gene expression , expression quantitative trait loci , gene expression profiling , microarray , genetics , phenotype , single nucleotide polymorphism , genotype , immunology , inflammation
for longitudinal ASL, DTI, APT and structural data. During imaging, anaesthesia was maintained using 1.5-2% isoflurane and 1L/min O 2. Results: At 4.5 months, prior to doxycycline treatment, we observed marked changes in CBF, ATP and diffusion in rTg4510s due to increased tau pathology in comparison toWT controls. This was most apparent in the CBF study. Following only one month of treatment to supress tau, (imaging at 5.5 months),CBF had returned to control levels. This pattern was also observed for APT and diffusion imaging and the trend continued through to 7.5 months. Conclusions: This study demonstrates the sensitivity of multi-parametric MRI to the regulation of tau-driven pathological processes and provides an opportunity to assess novel therapeutic strategies. These approaches could give insights into the early onset of tauopathies, at a time when non-invasive imaging biomarkers are urgently needed for understanding the progressive pathology. This is the first demonstration that suppression of tau expression can be observed with the clinically relevant MRI parameters CBF, ATP and diffusion.